The Australia cardiovascular devices market was valued at USD 941.97 Million in 2025 and is expected to grow at a CAGR of 4.20%, reaching USD 1421.39 Million by 2035. The market is supported by advanced healthcare infrastructure and increasing adoption of minimally invasive procedures. Growing aging population and the high prevalence of cardiovascular diseases are enhancing product demand. Rising investments in innovative cardiac implants and diagnostic tools, along with government support for healthcare modernization, are likely to boost market expansion over the forecast period.
Base Year
Historical Period
Forecast Period
According to the Heart Foundation, nearly 430,000 Australians are expected to experience a heart attack in their lifetime, with heart attacks causing 4% of all deaths, driving significant growth in Australia’s cardiovascular devices market.
In February 2024, the Australian Government invested Australian USD 50 million in the Artificial Heart Frontiers Program to develop a Total Artificial Heart, a move expected to accelerate innovation and significantly drive cardiovascular devices market growth.
Technological advancements, rising cardiovascular cases, and increased healthcare investments are driving market growth in Australia’s cardiovascular devices sector, with key players expanding offerings and adopting innovative strategies to enhance their market presence.
Compound Annual Growth Rate
4.2%
Value in USD Million
2026-2035
*this image is indicative*
Cardiovascular devices play a critical role in the diagnosis, monitoring, and treatment of heart and blood vessel-related conditions, supporting both acute care and long-term disease management. In Australia, the cardiovascular devices market is driven by a rising geriatric population, increasing cardiovascular disease prevalence, and advancements in medical technology. Strong healthcare infrastructure and growing awareness further support market expansion. The market was valued at USD 941.97 Million in 2025, reflecting significant investment in innovative solutions and improved patient outcomes. Continued research and public health initiatives are expected to strengthen the adoption of advanced cardiovascular interventions across the country.
High Disease Burden and Healthcare Costs Propel Growth of the Australia Cardiovascular Devices Market
The substantial and ongoing burden of cardiovascular disease (CVD), particularly in rural and remote areas, is a key factor driving the growth in the market. As reported by the Heart Research Institute in 2023, over 4 million Australians, approximately 1 in 6 are living with CVD, with 1.2 million affected by multiple related conditions. That year, CVD accounted for 1.2 million hospitalizations and an estimated 666,000 years of healthy life lost. With an annual cost of AUD 12.7 billion to the healthcare system, this significant disease and economic impact is accelerating the demand for innovative cardiovascular devices across the country.
Some of the trends in the market include advancements in cardiac innovation and the regulatory approvals of next-generation stents.
Innovations in Australia to Accelerate Market Value
Rising focus toward advanced heart failure solutions is driving innovation in Australia’s cardiovascular devices market. In February 2024, Monash University launched the Artificial Heart Frontiers Program, supported by a USD 50 million grant from the Medical Research Future Fund. Focused on developing next-generation implantable devices, including a Mini-Pump and Total Artificial Heart, the initiative positions Australia as a leader in cardiac technology. This national effort is expected to strengthen domestic manufacturing, improve patient outcomes, and substantially boost market growth across the cardiovascular devices sector.
Regulatory Approvals of Advanced Stents are Likely to Enhance Australia Cardiovascular Devices Market Value
The growing regulatory approval of technologically advanced drug-eluting stents (DES), reinforcing innovation in coronary healthcare is a notable trend in the market. In September 2024, SMT’s Supraflex Cruz DES received approval from the Therapeutic Goods Administration (TGA), highlighting Australia's openness to globally recognized cardiovascular solutions. The stent’s advanced design and clinical efficacy reflect a broader movement toward next-generation treatment options. This trend is expected to significantly boost market value by improving patient outcomes and expanding therapeutic choices across the country.
Coronary Artery Disease Segment to Witness Substantial Growth
By application, the market is segmented by application into coronary artery disease (CAD), heart failure, and others. Each address distinct therapeutic needs within the cardiovascular spectrum. Among these, coronary artery disease is expected to dominate the market, driven by its high prevalence and substantial healthcare impact. According to Louis W. Wang (2025), CAD was the leading cause of disease burden among Australian males and the fifth among females in 2023. This alarming statistic highlights the urgent need for effective treatment solutions. As a result, the demand for innovative coronary devices, such as drug-eluting stents, balloon catheters, and advanced angioplasty systems, continues to surge, positioning CAD as the leading application segment in the forecast period.
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Boston Scientific Corporation is a key player in Australia’s cardiovascular devices market, offering advanced solutions in interventional cardiology, electrophysiology, and structural heart therapies. Its portfolio includes coronary stents, transcatheter valves, and cardiac rhythm management devices widely adopted across Australian hospitals. With a focus on innovation and clinical outcomes, Boston Scientific supports the country’s growing demand for minimally invasive cardiovascular treatments, aligning with the shift toward advanced patient care technologies.
Abbott holds a strong presence in the Australian cardiovascular devices market through its broad product portfolio spanning vascular, structural heart, and cardiac rhythm management solutions. The company’s innovations, such as drug-eluting stents, MitraClip for mitral valve repair, and advanced diagnostic systems, are widely used across Australian healthcare facilities. Abbott’s focus on clinical research, regulatory partnerships, and local distribution networks strengthens its role in meeting Australia’s rising cardiovascular healthcare needs.
Medtronic is a market leader in cardiovascular devices in Australia, offering a comprehensive range of technologies for coronary intervention, heart failure management, electrophysiology, and structural heart disease. Its solutions include pacemakers, defibrillators, transcatheter aortic valve replacement (TAVR) systems, and stents. With strong collaborations across Australian hospitals and research institutions, Medtronic plays a pivotal role in improving patient outcomes while advancing access to next-generation cardiovascular care solutions nationwide.
B. Braun SE contributes significantly to Australia’s cardiovascular devices market through its wide-ranging portfolio of interventional and surgical solutions. The company provides products for vascular access, cardiopulmonary surgery, and infusion therapy, supporting both acute and long-term cardiovascular care. By combining German engineering expertise with localized distribution networks, B. Braun enhances the availability of reliable, high-quality cardiovascular devices in Australia, reinforcing its position as a trusted partner in the country’s healthcare system.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Cardinal Health, Terumo Corporation, LivaNova PLC, Siemens Healthcare Private Limited, GE HealthCare, Edwards Lifesciences Corporation, Koninklijke Philips N.V., and BD.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Device Type
Market Breakup by Application
Market Breakup by End User
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Device Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share